Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × futuximab × Clear all
NCT02540161 2020-08-05

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Duke University

Phase 2 Completed
43 enrolled 14 charts
CNS

Glioblastoma, Glioma

NCT02083653 2019-04-16

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Symphogen A/S

Phase 2 Completed
254 enrolled 21 charts
Gastrointestinal

Colorectal Neoplasms

NCT01417936 2018-10-15

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Symphogen A/S

Phase 2 Completed
26 enrolled 20 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡